The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Despite recent advances in first-line chemotherapy for advanced pancreatic cancer, standard treatment after the failure of initial chemotherapy has not been established. Hence, we aimed to retrospectively analyze the clinical characteristics and outcomes of second-line chemotherapy in patients with advanced pancreatic cancer. Methods: We reviewed the clinical data of patients with advanced pancreatic cancer who underwent palliative chemotherapy at Kosin University Gospel Hospital between January 2013 and October 2020. Results: Among 366 patients with advanced pancreatic cancer who had received palliative chemotherapy, 104 (28.4%) underwent at least one cycle of second-line chemotherapy. The median age of the patients at the time of initiating second-line treatment was 62 years (interquartile range, 57–62 years), and 58.7% (61 patients) of them were male. The common second-line chemotherapy regimens were 5-fluorouracil (FU) plus leucovorin, irinotecan, and oxaliplatin (33 patients, 31.7%); gemcitabine/nab-paclitaxel (29, 27.9%), gemcitabine±erlotinib (13, 12.5%); and oxaliplatin and 5-FU/leucovorin (12, 11.5%). The median overall survival (OS) and progression-free survival were 6.4 months (95% confidence interval [CI], 4.5–8.6 months) and 4.5 months (95% CI, 2.7–6.3 months), respectively. In a multivariate analysis, poor performance status (PS) (hazard ratio [HR], 2.247; p=0.021), metastatic disease (HR, 2.745; p=0.011), and elevated carcinoembryonic antigen (CEA) levels (HR, 1.939; p=0.030) at the beginning of second-line chemotherapy were associated with poor OS. Conclusion: The survival outcome of second-line chemotherapy for advanced pancreatic cancer remains poor. However, PS, disease extent (locally advanced or metastatic), and CEA level may help determine patients who could benefit from second-line treatment.
Abstract
Background: Despite recent advances in first-line chemotherapy for advanced pancreatic cancer, standard treatment after the failure of initial chemotherapy has not been established. Hence, we aimed to retrospectively analyze the clinical characteristics and outcomes of second-line chemotherapy in patients with advanced pancreatic cancer. Methods: We reviewed the clinical data of patients with advanced pancreatic cancer who underwent palliative chemotherapy at Kosin University Gospel Hospital between January 2013 and October 2020. Results: Among 366 patients with advanced pancreatic cancer who had received palliative chemotherapy, 104 (28.4%) underwent at least one cycle of second-line chemotherapy. The median age of the patients at the time of initiating second-line treatment was 62 years (interquartile range, 57–62 years), and 58.7% (61 patients) of them were male. The common second-line chemotherapy regimens were 5-fluorouracil (FU) plus leucovorin, irinotecan, and oxaliplatin (33 patients, 31.7%); gemcitabine/nab-paclitaxel (29, 27.9%), gemcitabine±erlotinib (13, 12.5%); and oxaliplatin and 5-FU/leucovorin (12, 11.5%). The median overall survival (OS) and progression-free survival were 6.4 months (95% confidence interval [CI], 4.5–8.6 months) and 4.5 months (95% CI, 2.7–6.3 months), respectively. In a multivariate analysis, poor performance status (PS) (hazard ratio [HR], 2.247; p=0.021), metastatic disease (HR, 2.745; p=0.011), and elevated carcinoembryonic antigen (CEA) levels (HR, 1.939; p=0.030) at the beginning of second-line chemotherapy were associated with poor OS. Conclusion: The survival outcome of second-line chemotherapy for advanced pancreatic cancer remains poor. However, PS, disease extent (locally advanced or metastatic), and CEA level may help determine patients who could benefit from second-line treatment.
참고문헌 (26)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von HoffDD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Oettle H, "Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial", J Clin Oncol, 32, pp.2423~2429 (2014)
- Gill S, "PANCREOX : a randomized phase III study of fluorouracil", leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy, 2016, pp.34, 3914~3920
- Wang-Gillam A, "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy(NAPOLI-1) : a global, randomised, open-label, phase 3 trial", Lancet, 387, pp.545~557 (2016)
- Ramaswamy A, "Outcomes with second-line chemotherapy in advanced pancreatic cancers : a retrospective study from a tertiary cancer center in India", Indian J Cancer, 55, pp.144~147 (2018)
- Tsang ES, "Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer", Am J Clin Oncol, 42, pp.196~201 (2019)
- Gränsmark E, "Real world evidence on second-line palliative chemotherapy in advanced pancreatic cancer", Front Oncol, 10, pp.1176~ (2020)
- Nagrial AM, "Second-line treatment in inoperable pancreatic adenocarcinoma : a systematic review and synthesis of all clinical trials", Crit Rev Oncol Hematol, 96, pp.483~497 (2015)
- Rahma OE, "Second-line treatment in advanced pancreatic cancer : a comprehensive analysis of published clinical trials", Ann Oncol, 24, pp.1972~1979 (2013)
- Pelzer U, "Best supportive care(BSC)versus oxaliplatin, folinic acid and 5-fluorouracil(OFF)plus BSC in patients for second-line advanced pancreatic cancer : a phase III-study from the German CONKO-study group", Eur J Cancer, 47, pp.1676~1681 (2011)
- Kim ST, "A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy", Clin Oncol(R Coll Radiol), 24, pp.105~111 (2012)
- Sinn M, "Second-Line treatment in pancreatic cancer patients:who profits? Results from the CONKO Study Group", Pancreas, 45, pp.601~605 (2016)
- Vienot A, "Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma", J Natl Cancer Inst, 109 (2017)[DOI]
- Hsu CC, "Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy", J Gastroenterol Hepatol, 35, pp.1694~1703 (2020)
- Jeung Eun Lee, "Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer", Gut and Liver, 14(1), pp.135~143 (2020), 거트앤리버 소화기연관학회협의회
- Colloca G, "Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer : a trial-level meta-analysis", Asia Pac J Clin Oncol (2021)[DOI]
- Sohal D, "Metastatic pancreatic cancer : ASCO clinical practice guideline update", J Clin Oncol, 36, pp.2545~2556 (2018)
- Ducreux M, "Cancer of the pancreas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v56~v68 (2015)
- Kim JH, "Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study", Cancer Commun(Lond), 38, pp.32~ (2018)
- Portal A, "Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure : an AGEO prospective multicentre cohort", Br J Cancer, 113, pp.989~995 (2015)
- da Rocha Lino A, "Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer : a retrospective analysis", J Gastrointest Oncol, 6, pp.511~515 (2015)
- Viaud J, "Gemcitabine as second-line chemotherapy after FOLFIRINOX failure in advanced pancreatic adenocarcinoma : a retrospective study", Dig Liver Dis, 49, pp.692~696 (2017)
- Sarabi M, "Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma", Oncol Lett, 13, pp.4917~4924 (2017)